Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Clinical Studies: Phase I Program

 

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Recruiting;   Study ID: NCT00729664

PARP Inhibitor ABT-888 with Cisplatin and Vinorelbine (7161)
Phase I Study of ABT-888 (Veliparib) in Combination With Cisplatin and Vinorelbine (Navelbine) for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Investigator: Eve Rodler, MD;   Conditions: Advanced Breast Cancer;    Status: Recruiting;   Study ID: NCT01104259

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)

Investigator: Ajay K. Gopal, MD;   Conditions: Non-Hodgkin's Lymphoma (NHL);    Status: Recruiting;   Study ID: NCT01307267

GA101 (RO5072759) for Previously Untreated Chronic Lymphocytic Leukemia (2514)
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01300247

Dose-Escalation Study of MLN9708 (C16001) (UW08039)
An Open-Label, Dose Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies

Investigator: John Thompson, MD;   Conditions: Advanced Non-Hematologic Malignancies, Non Small Cell Lung Cancer, Head and Neck Cancer, Soft Tissue Sarcoma, Prostate Cancer;    Status: Closed;   Study ID: NCT00830869

AGS-16C3F Monotherapy for Renal Cell Carcinoma
A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

Investigator: John A. Thompson, MD;   Conditions: Renal Cell Carcinoma;    Status: Recruiting;   Study ID: NCT01672775

SGN-75 + Everolimus for Metastatic Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma

Investigator: John A. Thompson, MD;   Conditions: Renal Cell Carcinoma;    Status: Closed;   Study ID: NCT01677390

PF-04449913 w/ Chemotherapy for AML or MDS
A Phase 1B Study To Evaluate The Safety And Preliminary Efficacy Of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose Ara-C Or Decitabine In Patients With Acute Myeloid Leukemia Or High Risk Myelodysplastic Syndrome

Investigator: Vivian G. Oehler, MD;   Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01546038

MORAb-004 + Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma

Investigator: Robin L. Jones, MD;   Conditions: Metastatic Soft Tissue Sarcoma;    Status: Recruiting;   Study ID: NCT01574716

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer
A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer

Investigator: John A. Thompson, MD;   Conditions: Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer;    Status: Recruiting;   Study ID: NCT01727076

Imatinib and BKM120 for 3rd Line GIST Patients
A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib

Investigator: Robin L. Jones, MD;   Conditions: 3rd Line GIST;    Status: Recruiting;   Study ID: NCT01468688

PEGPH20 for Stage IV Untreated Pancreatic Cancer (2687)
A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer

Investigator: Sunil R. Hingorani, MD;   Conditions: Metastatic Pancreatic Cancer;    Status: Recruiting;   Study ID: NCT01839487

Veliparib for Subjects With Solid Tumors
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors

Investigator: Elizabeth Swisher, MD;   Conditions: High Grade Serous Ovarian Cancer, BRCA Mutated Breast Cancer;    Status: Recruiting;   Study ID: NCT01853306

Oral CFG920 for Castration Resistant Prostate Cancer
A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer

Investigator: Robert Bruce Montgomery, MD;   Conditions: Prostatic Neoplasms;    Status: Recruiting;   Study ID: NCT01647789

SGN-LIV1A for Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01969643

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

BMS-986016 for Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas

Investigator: Ajay K. Gopal, MD;   Conditions: Hematologic Neoplasms;    Status: Pending;   Study ID: NCT01991184

MK-3475 + PegIFN-2b and MK-3475 + Ipilimumab
A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)

Investigator: John Thompson, MD;   Conditions: Renal Cell Carcinoma, Melanoma;    Status: Recruiting;   Study ID: NCT02089685